Tiantian Hao

Title: Innovations in Antitumor Drug Delivery by Tiantian Hao

Introduction

Tiantian Hao is an accomplished inventor based in Tianjin, China. He has made significant contributions to the field of targeted drug delivery systems, particularly in the development of antitumor drugs. His innovative approach focuses on enhancing the efficacy and reducing the toxicity of cancer treatments.

Latest Patents

Tiantian Hao holds a patent for a "Ternary conjugate of antitumor drug, and synthesis and application." This patent discloses a targeted delivery system for a hydrophobic antitumor drug. The system utilizes conjugates of E-selectin polypeptide ligand, polyethylene glycol, and the antitumor drug, which are connected by different link bridges containing disulfide bonds. The patent details the synthesis of these conjugates, evaluation of their antitumor activity, and the characteristics of nanoparticles self-assembled from the conjugates in an aqueous solution. The conjugates are designed to actively target tumor sites through the E-selectin peptide ligand and can self-assemble into nanoparticles, allowing for passive targeting via the enhanced permeability and retention (EPR) effect. The results indicate that these conjugates exhibit significant antitumor activity while being less toxic to normal cells, and they have the potential to inhibit tumor cell adhesion to vascular endothelial cells.

Career Highlights

Tiantian Hao is affiliated with Tianjin University of Science and Technology, where he continues to advance research in drug delivery systems. His work has garnered attention for its potential applications in the development of effective antitumor therapies.

Collaborations

Tiantian Hao collaborates with notable colleagues, including Peng Yu and Na Guo, who contribute to his research endeavors. Their combined expertise enhances the innovative approaches taken in their projects.

Conclusion

Tiantian Hao's contributions to the field of antitumor drug delivery represent a significant advancement in cancer treatment. His innovative patent showcases the potential for targeted therapies that can improve patient outcomes while minimizing side effects.